TrialArthritis & rheumatology (Hoboken, N.J.)2018

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.

Michael E Weinblatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.